Masaoka staging is of prognostic relevance in type B3 / C thymomas

Anticancer Research

Volumn 24, Issue 6, 2004, Pages 4113-4119

  Luebke, T ^a   Beckurts, K T E ^a   Wickenhauser, C ^a   Schneider, P ^a   Hoelscher, A H ^a   Moenig, Stephan P ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Ki 67 LI; Thymic carcinoma; Thymoma; Thymoma classification

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MASAOKA STAGING; MEDIASTINUM TUMOR; MULTIMODALITY CANCER THERAPY; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; THYMOMA; TUMOR CLASSIFICATION; WORLD HEALTH ORGANIZATION; CLASSIFICATION; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; THYMOMA; THYMUS NEOPLASMS;

EID: 14944352293     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Masaoka A, Monden Y, Nakahara K and Tanioka T: Follow-up study of thymomas with special reference to their clinical stages. Cancer 48: 2485-92, 1981.
2. Quintanilla-Martinez L, Wilkins EW Jr, Choi N, Efird J, Hug E and Harris NL: Thymoma. Histologic subclassification is an independent prognostic factor. Cancer 74: 606-17, 1994.
3. Blumberg D, Burt ME, Bains MS, Downey RJ, Martini N, Rusch V and Ginsberg RJ: Thymic carcinoma: current staging does not predict prognosis. J Thorac Cardiovasc Surg 115: 303-8; discussion 308-9, 1998.
4. Wick MR, Scheithauer BW, Weiland LH and Bernatz PE: Primary thymic carcinomas. Am J Surg Pathol 6: 613-30, 1982.
5. Akoum R, Brihi E, Chammas S and Abigerges D: Results of radiation therapy for thymoma based on a review of 27 patients. Mol Immunol 39: 1115-9, 2003.
6. Gawrychowski J, Rokicki M, Gabriel A, Lackowska B and Czyzewski D: Thymoma - the usefulness of some prognostic factors for diagnosis and surgical treatment. Eur J Surg Oncol 26: 203-8, 2000.
7. Giaccone G: Treatment of thymoma and thymic carcinoma. Ann Oncol 11: 245-6, 2000.
8. Sonobe M, Nakagawa M, Ichinose M, Ikegami N, Nagasawa M and Shindo T: Thymoma. Analysis of prognostic factors. Jpn J Thorac Cardiovasc Surg 49: 35-41, 2001.
9. Venuta F, Rendina EA, Longo F, De Giacomo T, Anile M, Mercadante E, Ventura L, Osti MF, Francioni F and Coloni GF: Long-term outcome after multimodality treatment for stage III thymic tumors. Ann Thorac Surg 76: 1866-72; discussion 1872, 2003.
10. Hernandez-Ilizaliturri FJ, Tan D, Cipolla D, Connolly G, Debb G and Ramnath N: Multimodality therapy for thymic carcinoma (TCA): results of a 30-year single-institution experience. Am J Clin Oncol 27: 68-72, 2004.
11. Daniele O and Fornasiero A: Ifosfamide in thymic neoplasms. Oncology 65: 44-5, 2003.
12. Muller-Hermelink HK and Marx A: Thymoma. Curr Opin Oncol 12: 426-33, 2000.
13. Tateyama H, Eimoto T, Tada T, Hattori H, Murase T and Takino H: Immunoreactivity of a new CD5 antibody with normal epithelium and malignant tumors including thymic carcinoma. Am J Clin Pathol 111: 235-40, 1999.
14. Tateyama H, Eimoto T, Tada T, Inagaki H, Hattori H and Takino H: Apoptosis, bcl-2 protein, and Fas antigen in thymic epithelial tumors. Mod Pathol 10: 983-91, 1997.
15. Tateyama H, Eimoto T, Tada T, Mizuno T, Inagaki H, Hata A, Sasaki M and Masaoka A: p53 protein expression and p53 gene mutation in thymic epithelial tumors. An immunohistochemical and DNA sequencing study. Am J Clin Pathol 104: 375-81, 1995.
16. Hayashi Y, Ishii N, Obayashi C, Jinnai K, Hanioka K, Imai Y and Itoh H: Thymoma: tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21. Virchows Arch 426: 43-50, 1995.
17. Chen FF, Yan JJ, Jin YT and Su IJ: Detection of bcl-2 and p53 in thymoma: expression of bcl-2 as a reliable marker of tumor aggressiveness. Hum Pathol 27: 1089-92, 1996.
18. Chen FF, Yan JJ, Chang KC, Lai WW, Chen RM and Jin YT: Immunohistochemical localization of Mcl-1 and bcl-2 proteins in thymic epithelial tumours. Histopathology 29: 541-7, 1996.
19. Hino N, Kondo K, Miyoshi T, Uyama T and Monden Y: High frequency of p53 protein expression in thymic carcinoma but not in thymoma. Br J Cancer 76: 1361-6, 1997.
20. Fukai I, Masaoka A, Hashimoto T, Yamakawa Y, Mizuno T, Tanamura O, Hirokawa K and Ueda R: An immunohistologic study of the epithelial components of 81 cases of thymoma. Cancer 69: 2463-8, 1992.
21. Fukai I, Masaoka A, Hashimoto T, Yamakawa Y, Niwa H, Kiriyama M and Eimoto T: Differential diagnosis of thymic carcinoma and lung carcinoma with the use of antibodies to cytokeratins. J Thorac Cardiovasc Surg 110: 1670-5, 1995.
22. Baldus SE, Zirbes TK, Weingarten M, Fromm S, Glossmann J, Hanisch FG, Monig SP, Schroder W, Flucke U, Thiele J, Holscher AH and Dienes HP: Increased galectin-3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation. Tumour Biol 21: 258-66, 2000.
23. Pan CC, Ho DM, Chen WY, Huang CW and Chiang H: Ki67 labelling index correlates with stage and histology but not significantly with prognosis in thymoma. Histopathology 33: 453-8, 1998.
24. Gilhus NE, Jones M, Turley H, Gatter KC, Nagvekar N, Newsom-Davis J and Willcox N: Oncogene proteins and proliferation antigens in thymomas: increased expression of epidermal growth factor receptor and Ki67 antigen. J Clin Pathol 48: 447-55, 1995.
25. Kirchner T, Schalke B, Marx A and Muller-Hermelink HK: Evaluation of prognostic features in thymic epithelial tumors. Thymus 14: 195-203, 1989.
26. Suster S and Rosai J: Thymic carcinoma. A clinicopathologic study of 60 cases. Cancer 67: 1025-32, 1991.
27. Chung DA: Thymic carcinoma-analysis of nineteen clinicopathological studies. Thorac Cardiovasc Surg 48: 114-9, 2000.
28. Hsu CP, Chen CY, Chen CL, Lin CT, Hsu NY, Wang JH and Wang PY: Thymic carcinoma. Ten years' experience in twenty patients. J Thorac Cardiovasc Surg 107: 615-20, 1994.
29. Truong LD, Mody DR, Cagle PT, Jackson-York GL, Schwartz MR and Wheeler TM: Thymic carcinoma. A clinicopathologic study of 13 cases. Am J Surg Pathol 14: 151-66, 1990.
30. Schneider PM, Fellbaum C, Fink U, Bollschweiler E and Prauer HW: Prognostic importance of histomorphologic subclassification for epithelial thymic tumors. Ann Surg Oncol 4: 46-56, 1997.
31. Tomita M, Matsuzaki Y and Onitsuka T: Relationship between expression of cancer-related proteins and tumor invasiveness in thymoma. Eur J Cardiothorac Surg 21: 596, 2002.
32. Liu W, Tong T, Ji Z and Zhang Z: Long-term prognostic analysis of thymectomized patients with myasthenia gravis. Chin Med J (Engl) 115: 235-7, 2002.
33. Kondo K and Monden Y: Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 76: 878-84; discussion 884-5, 2003.
34. Blumberg D, Port JL, Weksler B, Delgado R, Rosai J, Bains MS, Ginsberg RJ, Martini N, McCormack PM, Rusch V et al: Thymoma: a multivariate analysis of factors predicting survival. Ann Thorac Surg 60: 908-13; discussion 914, 1995.
35. Okumura M, Ohta M, Tateyama H, Nakagawa K, Matsumura A, Maeda H, Tada H, Eimoto T, Matsuda H and Masaoka A: The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 94: 624-32, 2002.
36. Lardinois D, Rechsteiner R, Lang RH, Gugger M, Betticher D, von Briel C, Krueger T and Ris HB: Prognostic relevance of Masaoka and Muller-Hermelink classification in patients with thymic tumors. Ann Thorac Surg 69: 1550-5, 2000.
37. Pescarmona E, Rendina EA, Venuta F, D'Arcangelo E, Pagani M, Ricci C, Ruco LP and Baroni CD: Analysis of prognostic factors and clinicopathological staging of thymoma. Ann Thorac Surg 50: 534-8, 1990.
38. Kuo TT and Lo SK: Thymoma: a study of the pathologic classification of 71 cases with evaluation of the Muller-Hermelink system. Hum Pathol 24: 766-71, 1993.
39. Chen G, Marx A, Wen-Hu C, Yong J, Puppe B, Stroebel P and Mueller-Hermelink HK: New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 95: 420-9, 2002.
40. Matsushima S, Yamamoto H, Egami K, Suzuki S and Tanaka S: Evaluation of the prognostic factors after thymoma resection. Int Surg 86: 103-6, 2001.
41. Okumura M, Ohta M, Miyoshi S, Mori T, Yasumitsu T, Nakahara K, Iuchi K, Tada H, Maeda H and Matsuda H: Oncological significance of WHO histological thymoma classification. A clinical study based on 286 patients. Jpn J Thorac Cardiovasc Surg 50: 189-94, 2002.
42. Gerdes J: Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol 1: 199-206, 1990.
43. Salakou S, Tsamandas AC, Bonikos DS, Papapetropoulos T and Dougenis D: The potential role of bcl-2, bax, and Ki67 expression in thymus of patients with myasthenia gravis, and their correlation with clinicopathologic parameters. Eur J Cardiothorac Surg 20: 712-21, 2001.
44. Hannun YA: Apoptosis and the dilemma of cancer chemotherapy. Blood 89: 1845-53, 1997.
45. Evan G: Cancer - a matter of life and cell death. Int J Cancer 71: 709-11, 1997.
46. Hartsough MT, Clare SE, Mair M, Elkahloun AG, Sgroi D, Osborne CK, Clark G and Steeg PS: Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition. Cancer Res 61: 2320-7, 2001.
47. Tomita M, Matsuzaki Y, Edagawa M, Maeda M, Shimizu T, Hara M and Onitsuka T: Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. J Thorac Cardiovasc Surg 124: 493-8, 2002.